Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of sutimlimab in Japanese participants with cold agglutinin disease
jRCT2031210392Completed
- Sponsor
- Sanofi
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of sutimlimab in cold agglutinin disease (CAD), sponsored by Sanofi. Primary endpoints: Treatment-emergent adverse events and serious adverse events and Treatment-emergent adverse events of special interest. Started Dec 2021; status: completed.
02
Drugs
sutimlimab
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on jRCT2031210392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210392.